These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 31348982)

  • 21. The safety and efficacy of tazarotene gel, a topical acetylenic retinoid, in the treatment of psoriasis.
    Krueger GG; Drake LA; Elias PM; Lowe NJ; Guzzo C; Weinstein GD; Lew-Kaya DA; Lue JC; Sefton J; Chandraratna RA
    Arch Dermatol; 1998 Jan; 134(1):57-60. PubMed ID: 9449910
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical safety of tazarotene in the treatment of plaque psoriasis.
    Marks R
    J Am Acad Dermatol; 1997 Aug; 37(2 Pt 3):S25-32. PubMed ID: 9270553
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical pharmacokinetics and drug metabolism of tazarotene: a novel topical treatment for acne and psoriasis.
    Tang-Liu DD; Matsumoto RM; Usansky JI
    Clin Pharmacokinet; 1999 Oct; 37(4):273-87. PubMed ID: 10554045
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rapid Onset of Action in Patients With Moderate-to-Severe Plaque Psoriasis With Halobetasol 0.01%/Tazarotene 0.045% Fixed Combination.
    Stein Gold L; Kircik LH; Pariser D; Sugarman JL; Lin T; Kang R; Pillai R
    J Drugs Dermatol; 2018 Aug; 17(8):863-868. PubMed ID: 30124725
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Once-daily tazarotene gel versus twice-daily fluocinonide cream in the treatment of plaque psoriasis.
    Lebwohl M; Ast E; Callen JP; Cullen SI; Hong SR; Kulp-Shorten CL; Lowe NJ; Phillips TJ; Rosen T; Wolf DI; Quell JM; Sefton J; Lue JC; Gibson JR; Chandraratna RA
    J Am Acad Dermatol; 1998 May; 38(5 Pt 1):705-11. PubMed ID: 9591815
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetics of tazarotene and acitretin in psoriasis.
    Heath MS; Sahni DR; Curry ZA; Feldman SR
    Expert Opin Drug Metab Toxicol; 2018 Sep; 14(9):919-927. PubMed ID: 30134735
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combination of calcipotriene (Dovonex) ointment and tazarotene (Tazorac) gel versus clobetasol ointment in the treatment of plaque psoriasis: a pilot study.
    Bowman PH; Maloney JE; Koo JY
    J Am Acad Dermatol; 2002 Jun; 46(6):907-13. PubMed ID: 12063489
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A comparison of tazarotene 0.1% gel once daily plus mometasone furoate 0.1% cream once daily versus calcipotriene 0.005% ointment twice daily in the treatment of plaque psoriasis.
    Guenther LC; Poulin YP; Pariser DM
    Clin Ther; 2000 Oct; 22(10):1225-38. PubMed ID: 11110233
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bioavailability, antipsoriatic efficacy and tolerability of a new light cream with mometasone furoate 0.1%.
    Korting HC; Schöllmann C; Willers C; Wigger-Alberti W
    Skin Pharmacol Physiol; 2012; 25(3):133-41. PubMed ID: 22353786
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combination phototherapy of psoriasis with narrow-band UVB irradiation and topical tazarotene gel.
    Behrens S; Grundmann-Kollmann M; Schiener R; Peter RU; Kerscher M
    J Am Acad Dermatol; 2000 Mar; 42(3):493-5. PubMed ID: 10688723
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical efficacy and safety of tazarotene: optimizing clinical results.
    Lebwohl M
    Cutis; 1998 Feb; 61(2 Suppl):27-9. PubMed ID: 9787989
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nano-lipoidal carriers of tretinoin with enhanced percutaneous absorption, photostability, biocompatibility and anti-psoriatic activity.
    Raza K; Singh B; Lohan S; Sharma G; Negi P; Yachha Y; Katare OP
    Int J Pharm; 2013 Nov; 456(1):65-72. PubMed ID: 23973754
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The role of tazarotene in the treatment of psoriasis.
    Marks R
    Br J Dermatol; 1999 Apr; 140 Suppl 54():24-8. PubMed ID: 10731131
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Preparation, characterization, and
    Walunj M; Doppalapudi S; Bulbake U; Khan W
    J Liposome Res; 2020 Mar; 30(1):68-79. PubMed ID: 30897993
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety, efficacy and duration of therapeutic effect of tazarotene used in the treatment of plaque psoriasis.
    Weinstein GD
    Br J Dermatol; 1996 Oct; 135 Suppl 49():32-6. PubMed ID: 9035703
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tazarotene Revisited: Safety and Efficacy in Plaque Psoriasis and Its Emerging Role in Treatment Strategy.
    Tanghetti E; Lebwohl M; Stein Gold L
    J Drugs Dermatol; 2018 Dec; 17(12):1280-1287. PubMed ID: 30586259
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Halobetasol 0.01%/Tazarotene 0.045% Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis: Maintenance of Therapeutic Effect After Cessation of Therapy.
    J Drugs Dermatol; 2019 Aug; 18(8):815-820. PubMed ID: 31424713
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of tazarotene 0.1% gel plus petrolatum once daily versus calcipotriol 0.005% ointment twice daily in the treatment of plaque psoriasis.
    Tzung TY; Wu JC; Hsu NJ; Chen YH; Ger LP
    Acta Derm Venereol; 2005; 85(3):236-9. PubMed ID: 16040409
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Psoralen loaded liposomal nanocarriers for improved skin penetration and efficacy of topical PUVA in psoriasis.
    Doppalapudi S; Jain A; Chopra DK; Khan W
    Eur J Pharm Sci; 2017 Jan; 96():515-529. PubMed ID: 27777066
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Calcipotriol vs. tazarotene as combination therapy with narrowband ultraviolet B (311 nm): efficacy in patients with severe psoriasis.
    Schiener R; Behrens-Williams SC; Pillekamp H; Kaskel P; Peter RU; Kerscher M
    Br J Dermatol; 2000 Dec; 143(6):1275-8. PubMed ID: 11122033
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.